Pirfenidone (Esbriet®, Pirfenex®, Pirespa®)

Status
To Patients
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

Pirfenidone (Esbriet®, Pirfenex®, Pirespa®): Pirfenidone is an antifibrotic and anti-inflammatory drug approved to treat IPF in the US, Europe, Canada, Asia, and Australia. In clinical trials, pirfenidone has been shown to slow progression of mild-to-moderate idiopathic pulmonary fibrosis. It is taken by mouth three times a day. 

More Information

PFF Pirfenidone Fact Sheet

ESBRIET.com

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >